ClinicalTrials.gg
RecruitingNCT06848946Updated Jan 21, 2026

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

A Phase 4 interventional study of iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery and Sham procedure in conjunction with cataract surgery in Glaucoma, Open-angle, Ocular Hypertension (OHT) and Phacoemulsification Cataract Surgery, sponsored by Glaukos Corporation. Recruiting at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Glaukos Corporation · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Planned enrollment
24th of 45
132 · median 135
Started
2025
the only one that year
Phase 4
22 of 46
2 open now
Registered
45th of 46
by date
Lead sponsor
7 of 46
Glaukos Corporation

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 24th largest by planned enrollment of the 45 interventional ones that give a count, is the only one that started in 2025, is one of 22 in phase 4, and was the 45th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone

Read the detailed description

This is a Phase 4 randomized, double-masked, parallel group trial designed to evaluate the safety and IOP-lowering efficacy of administering iDose TR (travoprost intracameral implant 75 mcg) in conjunction with uncomplicated cataract surgery (phacoemulsification with a posterior chamber intraocular lens) compared to uncomplicated cataract surgery alone, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

03

Conditions studied

  • Glaucoma, Open-angle
  • Ocular Hypertension (OHT)
  • Phacoemulsification Cataract Surgery
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cataract diagnosis: age-related cataract eligible for phacoemulsification in the study eye.
  • OAG or OHT diagnosis: either OAG (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or OHT in the study eye (i.e., eye to undergo cataract surgery)

Exclusion criteria

Exclusion Criteria:

  • Active corneal inflammation or edema.
  • Retinal disorders not associated with glaucoma.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Active comparator
    iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery

    iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery

    Combination Product: iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery

  • Sham comparator
    Sham procedure in conjunction with cataract surgery

    Sham procedure in conjunction with cataract surgery

    Procedure: Sham procedure in conjunction with cataract surgery

Interventions

  • Combination productiDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery

    Drug page: Travoprost

    iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery

  • ProcedureSham procedure in conjunction with cataract surgery

    Sham procedure in conjunction with cataract surgery

06

What researchers measure

Primary outcomes

  1. Change from baseline in mean diurnal IOP

    Mean diurnal IOP at the Month 3 Visit minus mean diurnal IOP at the Baseline Visit

    Time frame: 3 Months

07

Study locations

1 of 1 sites recruiting
  • Glaukos Investigator Site
    Kenosha, Wisconsin 53142, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Aug 2026, 19 months after the start.

Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 19 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2025
First posted
Feb 27, 2025
StartActual
Jan 13, 2025
Primary completionEst.
Aug 2026
CompletionEst.
Jun 2027
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06848946
Responsible party
Sponsor
First posted
Feb 27, 2025
Start date
Jan 13, 2025
Primary completion
Aug 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jan 21, 2026

Study contacts

Study Manager
Contact
ClinicalResearch@glaukos.com
949-739-8749
Study Director
study chair · Glaukos Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion